ReviewCureus2026
Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a chronic disease associated with increased cardiometabolic risk, reduced quality of life, and higher mortality. Although injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) have substantially improved weight management, the requirement for injections remains a limitation for many patients. Orforglipron is a novel nonpeptide oral GLP-1RA currently under investigation for the treatment of overweight, obesity, and type 2 diabetes mellitus (T2DM). This systematic review evaluated the efficacy and safety of oral orforglipron in adults with overweight or obesity, with or without T2DM. A structured literature search was conducted using PubMed and ScienceDirect from database inception through December 2025. Randomized controlled trials evaluating oral orforglipron and reporting weight-related, glycemic, or metabolic outcomes were included. Six randomized controlled trials involving 6,022 participants were included in the qualitative synthesis, with follow-up durations ranging from 12 to 72 weeks. Across studies, treatment with orforglipron was associated with clinically meaningful reductions in body weight ranging from approximately -4.5% to -14.7%, with greater reductions generally observed in longer-duration studies and at higher doses. Improvements in glycated hemoglobin (HbA1c), fasting glucose, waist circumference, systolic blood pressure, triglycerides, and non-high-density lipoprotein cholesterol were also reported across several studies. Gastrointestinal adverse events, particularly nausea, vomiting, diarrhea, and constipation, were the most commonly reported safety outcomes and occurred more frequently during dose escalation and in higher-dose groups. Overall, current evidence suggests that oral orforglipron may represent a promising therapeutic option for weight reduction and glycemic improvement in adults with overweight or obesity; however, additional long-term randomized controlled trials are needed to further clarify optimal dosing strategies, long-term safety, and comparative clinical effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.